Metabolic Dysfunction-Associated Liver Diseases

Questions discussed in this category

How does presence of clinically significant portal hypertension change patient prognosis in MASLD?

1 Answer available

If you do not have easy access to Fibroscan, what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk stratify them?

1 Answer available

Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?

1 Answer available

How do you approach an obese patient on long-term methotrexate with normal liver tests in terms of workup for underlying fatty liver?

Would you start with a baseline ultrasound and then pursue further workup such as fibroscan if fatty liver is present, or other?

1 Answer available

Papers discussed in this category

International journal of molecular sciences, 2022 Mar 13

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.

Related Topics